CMR Short Reviews
- The Concept of CMR
  Historical background on global cardiometabolic risk, epidemiological aspects of obesity and type 2 diabetes, ABCs of cardiovascular disease risk factors, intra-abdominal adiposity, metabolic syndrome and contribution to cardiometabolic risk.
- Evaluating CMR
  Research and clinical tools to identify individuals with excess intra-abdominal adiposity and quantify their risk of diabetes and cardiovascular disease (global cardiometabolic risk).
- Managing CMR
  Notions and practical tools to better manage the abdominally obese patient with excess intra-abdominal adiposity and related clustering abnormalities.
Documentation Centre
- Slides, videos and more

Documentation Centre

August 30, 2007: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-61; Lamarche B, Tchernof A, Mauriège P et al.

Description of this Publication

Results of the prospective Québec Cardiovascular Study involving middle-aged men provided evidence that a triad of non-traditional metabolic risk factors (i.e., elevated fasting insulin and apolipoprotein B levels as well as small LDL particles) could predict ischemic heart disease risk beyond conventional lipid variables. These results highlighted the potential value of these features of the metabolic syndrome in predicting coronary heart disease (CHD) risk.

By clicking on this link, you will leave the INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK website

Key Words
Metabolic Syndrome, Cardiovascular Disease

The content of this website is provided for educational and informational purposes only and is not to be used for medical advice, diagnosis or treatment. Use of this site is subject to the terms and conditions contained in our Legal Notices.